Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer
I. V. Scholz(Ludwig-Maximilians-Universität München), Christine Spitzweg(Mayo Clinic), Konstantin Maletz(Ludwig-Maximilians-Universität München), Richard G. Vile(Mayo Clinic), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Neziha Cengic(Ludwig-Maximilians-Universität München), Elizabeth R. Bergert, James C. Morris(Clemson University), Burkhard Göke(Ludwig-Maximilians-Universität München), Claire Baker(Mayo Clinic)
Cited by 74
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Inhibition of Trypanosoma brucei Gene Expression by RNA Interference Using an Integratable Vector with Opposing T7 Promoters
|Journal of Biological Chemistry|2000|532